22 results about "Antibody hypervariable region" patented technology

The present invention discloses a subunit vaccine against chicken infectious anemia virus, belonging to the technical field of animal disease vaccines. The present invention provides a subunit vaccine against chicken infectious anemia virus, and the active ingredient is a recombinant fusion protein of the B cell epitope of chicken infectious anemia virus VP1 protein and Salmonella typhimurium flagellin. The B cell epitope of chicken infectious anemia virus VP1 protein is obtained by connecting the B cell antigen epitopes contained in chicken infectious anemia virus VP1 protein through a linker peptide. The Salmonella typhimurium flagellin is obtained by deleting the hypervariable region of Salmonella typhimurium flagellin FliC. After the fusion expression protein of the present invention is administered to 1-day-old SPF chickens, it can induce the production of specific IgG antibodies, and after 28 days of immunization, the immunized chicken flock can resist the challenge of the virulent strain of chicken infectious anemia virus, and 70% of the challenged chicken flock is protected from disease. The present invention has great potential for clinical prevention and control of chicken infectious anemia virus infection.

This invention relates to the field of bioengineering technology, specifically to a recombinant adenovirus displaying a large antigen fragment on its capsid surface, its construction method, and its applications. The HVR1 and HVR5 regions of the hexon hypervariable region of this virus are replaced by gene fragments containing exogenous genes; each exogenous gene fragment has a flexible linker attached to both ends, and the gene sequence of the flexible linker is shown in SEQ ID No. 1. By precisely locating the naturally variable HVR1 and HVR5 loop regions exposed on the surface of the hexon protein as insertion sites, and supplementing them with flexible linkers, the core problem of exogenous sequence insertion disrupting the stability of the hexon structure is successfully solved. This allows for stable packaging to produce viral particles with high titers and infectivity, enabling the development of a new generation of highly efficient and safe capsid-displaying adenovirus vaccines.

To provide an engineered meganuclease that recognizes and cleaves the recognition sequence in the human T cell receptor alpha constant region gene.SOLUTION: Provided herein is an engineered meganuclease comprising a first subunit and a second subunit, where the first subunit binds to a first recognition half site of a specific sequence in human T cell receptor alpha constant region gene and comprises a first hypervariable region, and the second subunit binds to a second recognition half site of the specific sequence comprising the specific sequence and comprises a second hypervariable region, where the second hypervariable region has (a) at least 81% sequence homology to an amino acid sequence corresponding to residues 24 to 79 of a specific sequence or (b) at least 86% sequence homology to an amino acid sequence corresponding to residues 24 to 79 of a specific sequence.SELECTED DRAWING: None

The invention discloses a strain identification method based on a 16S rRNA (ribosomal Ribonucleic Acid) hypervariable region. According to the invention, a plurality of hypervariable regions of 16S rRNA are integrated, the distinguishing ability of specific strains in different variable regions and other strains belonging to the same genus is researched through a molecular evolutionary tree method, and finally, the combination of different hypervariable regions can be found, so that the purpose of identifying the specific strains at the species level is achieved.

The invention discloses a microbial community identification method and system, and particularly relates to the technical field of microbiomics. A hidden Markov model database constructed on the basis of multiple types of ribosome RNA sequences is adopted for global search, a huge whole genome database in the prior art is replaced, and the size of the database is reduced; moreover, the hypervariable region sequence is extracted from the identified ribosome RNA sequence in a targeted manner, and the extracted sequence data and the quality information in the original sequencing data are pasted back, so that the hypervariable region sequence file containing the complete quality information is generated. The sequence data contains sequence information for identification, and a ribosome RNA marker gene sequence can be accurately identified and extracted from metagenome or metatranscriptome sequencing data; the original sequencing data can be used for a traditional amplicon analysis process, and can also support downstream deep analysis, so that seamless connection with the traditional amplicon analysis process is realized.

The disclosure relates, inter alia, to recombinant adenoviruses having capsid proteins engineered to include an albumin-binding moiety such that the albumin-binding moiety is present on the outer surface of the recombinant adenovirus capsids. Also described are pharmaceutical compositions comprising the recombinant adenoviruses, and methods of using the recombinant adenoviruses to treat genetic diseases and disorders.

The invention provides a sheep-derived component rapid quantitative detection method based on dual real-time fluorescent PCR. According to the method, a single-copy nuclear gene GAPDH is taken as a target spot, a sheep specific primer and a probe are designed in a hypervariable region of the single-copy nuclear gene GAPDH, and an internal reference primer and a probe capable of identifying various common animal-derived components are designed in a conserved region of the single-copy nuclear gene GAPDH. As the target and the internal reference are located in the same gene and coexist in the same cell according to the proportion of 1: 1, quantitative deviation caused by gene copy number difference or expression fluctuation in a traditional two-step method is remarkably reduced. The detection strategy constructed by the invention has double advantages of specific recognition and broad-spectrum reference, is clear in quantitative basis and simple and convenient to operate, is suitable for rapid recognition and quantitative adulteration analysis of sheep-derived components in meat products, and has wide application prospects and supervision values.

The invention provides preparation and application of an adenovirus non-structural protein, and aims at a novel chimpanzee adenovirus to screen the non-structural protein capable of detecting the titer of the chimpanzee adenovirus with high sensitivity and strong specificity. Immunofluorescence detection is carried out on the virus titer through the antibody prepared from the non-structural protein, the result is close to the detection result of a fluorescence counting method of flow cytometry, compared with detection of hypervariable region protein antibodies and whole virus antibodies in existing structural protein, the accuracy and sensitivity of detection are remarkably improved, very high specificity can be kept, and the method is suitable for large-scale popularization and application. Therefore, the chimpanzee adenovirus titer can be detected more simply, conveniently and efficiently.

Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.

The present invention discloses a forensic genetic marker detection kit based on high-throughput sequencing and its use method. The kit contains specific amplification primers for 199 genetic markers and can simultaneously detect four types of forensic genetic markers: autosomal STRs, Y-chromosome STRs, X-chromosome STRs, and mitochondrial mtDNA hypervariable regions. Compared with existing technologies, the kit of the present invention solves the problem of being unable to simultaneously detect a large number of forensic genetic markers, including autosomal STRs, Y-chromosome STRs, X-chromosome STRs, and mitochondrial mtDNA. It increases the genetic information that can be obtained in a single test, provides more genetic information data for the identification of kinship and the detection of difficult cases, and can meet the needs of actual case inspection, DNA database construction, and paternity testing.

The present invention discloses an antibody detection kit for CD biological agents and a preparation method thereof, which relates to the technical field of immunoassay. The kit includes an antibody capture device and an antibody detection device. The antibody capture device includes a solid-phase carrier coated with CD biological agents, and the antibody detection device is a cellulose membrane immobilized with functional fragments or a conjugate conjugated with functional fragments; the functional fragments are variable regions or heavy chain variable regions or heavy chain hypervariable regions of CD biological agents. The present invention overcomes the false positive and false negative defects in the prior art. By coating CD biological agents on the capture device, the occurrence of false positives is avoided. The inventor sets that the detection antigen with a small molecular weight, such as the variable region, heavy chain variable region or complementarity-determining region of CD biological agents, has the advantages of small steric hindrance and easy binding to the Fab of anti-antibody, making the detection sensitivity higher and achieving the purpose of companion diagnosis of CD biological agent drugs. Thus, the phenomenon of false negatives is avoided.

The invention concerns a modified oncolytic adenovirus of serotype Ad5; a pharmaceutical composition comprising same; and a method of treating cancer using same wherein said modified adenovirus comprises at least one point mutation(s) in the hexon hypervariable region 7 (HVR7 mutation) to prevent virus binding with coagulation factor 10 (FX); at least one point mutation(s) in the fiber knob region AB loop (KO1 mutation) to prevent virus binding with the coxsackie and adenovirus receptor (CAR); and at least one point mutation(s) in the penton integrin binding motif Arg-Gly-Asp (RGD) to prevent virus binding with αvβ3 / αvβ5 integrin.

The invention discloses an Ad4-55 / Ad7-3 type tetravalent recombinant adenovirus vaccine and an application of the Ad4-55 / Ad7-3 type tetravalent recombinant adenovirus vaccine. The preparation method comprises the following steps: replacing a fifth hypervariable region of an HAdV-4 hexon in an HAdV-4 genome with a second hypervariable region of an HAdV-55 hexon to obtain a recombinant adenovirus Ad4-55; and replacing the first hypervariable region of the HAdV-7 hexon in the HAdV-7 genome with the first hypervariable region of the HAdV-3 hexon, so as to obtain the recombinant adenovirus Ad7-3. And mixing the recombinant adenovirus Ad4-55 and the recombinant adenovirus Ad7-3 to obtain the tetravalent recombinant adenovirus vaccine. Experiments prove that when the tetravalent recombinant adenovirus vaccine prepared by the invention is used for immunizing mice, high-level specific IgG antibodies and neutralizing antibodies can be induced. According to the present invention, the important application value is provided for the prevention and control of HAdV-3, HAdV-7, HAdV-4 and HAdV-55.

The present invention provides a library containing synthetic polynucleotides encoding antibody heavy chains (e.g., heavy chains of dynamic human antibodies), as well as antibody heavy chains, antibodies, cells, animals, methods, and kits related thereto. [Solution] Provided herein is a library containing polynucleotides, one of which encodes an antibody heavy chain containing specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein is a library containing polynucleotides encoding a plurality of unique antibodies, each antibody containing a heavy chain variable region and a light chain variable region. Also provided relating to the antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods for constructing antibody libraries, kits, and methods for producing bispecific antibodies.

The invention discloses a primer combination for simultaneously detecting enterovirus D68 and rhinovirus, belongs to the technical field of molecular biology, and aims to solve the problems of low single pathogen detection efficiency, remarkable cross reaction, HRV-C type missing detection and the like in the prior art. An HRV 5 'UTR conserved region and an EV-D68 VP1 gene hypervariable region are analyzed and screened as targets through bioinformatics; the nucleotide sequences of the specific primer aiming at the enterovirus D68 obtained by designing and screening are shown as SEQ ID NO: 1-SEQ ID NO: 2, and the nucleotide sequence of the probe is shown as SEQ ID NO: 3; the nucleotide sequences of the specific primer aiming at the rhinovirus are as shown in SEQ ID NO: 4-SEQ ID NO: 5, and the nucleotide sequence of the probe is as shown in SEQ ID NO: 6; the method is high in detection sensitivity and low in cost, and specificity verification shows that the method has no cross reaction with other genotypes of enteroviruses and common respiratory pathogens.

The invention relates to the technical field of bioengineering, in particular to the technical field of bioengineering, and particularly relates to a recombinant adenovirus with a capsid surface displaying an oversized fragment antigen, a construction method and application. An HVR1 region and an HVR5 region of a Hexon hypervariable region of the virus are respectively replaced by gene segments containing exogenous genes; in the gene segment, the two ends of the exogenous gene are respectively connected with a flexible connection segment, and the gene sequence of the flexible connection segment is as shown in SEQ ID No.1. HVR1 and HVR5 ring regions which are accurately positioned to be exposed on the surface of Hexon protein and have natural variability are used as insertion sites, and a flexible connecting fragment is supplemented, so that the core problem that the stability of a Hexon structure is damaged by insertion of an exogenous sequence is successfully solved, and virus particles with high titer and infection activity can be stably packaged and produced; a new generation of efficient and safe capsid display type adenovirus vaccine can be developed.

This application describes a technology relating to treating neurofibromatosis type 1 and particularly, but not exclusively, to compositions and methods for gene replacement therapy treatments of patients having NF1-related tumors, for example, new recombinant adeno-associated virus vectors comprising a neurofibromatosis type 1 GAP-related domain fused to a Ras hypervariable region and use thereof to treat neurofibromatosis type 1.

This invention relates to the field of biological protein application technology, and discloses the application of flagellin hypervariable region H as an intramolecular adjuvant in vaccine preparation. The amino acid sequence of flagellin hypervariable region H is shown in SEQ ID NO.3, and the nucleotide sequence of the gene encoding flagellin hypervariable region H is shown in SEQ ID NO.4. This invention also discloses an expression cassette, recombinant vector, recombinant cells, or recombinant bacteria containing the gene encoding flagellin hypervariable region H. This invention uses the aforementioned flagellin hypervariable region H as an intramolecular adjuvant in vaccine preparation. This invention connects flagellin hypervariable region H to an antigenic epitope to obtain a fusion protein. Compared with existing technologies, the solubility and activity of the fusion protein are improved. Simultaneously, this invention overcomes the expression form of inclusion bodies in existing E. coli expression systems, eliminating the need for subsequent refolding and assembly, thus simplifying the vaccine preparation process.

Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.

The present specification provides a library comprising polynucleotides, wherein one of the polynucleotides encodes an antibody light chain having specific hypervariable regions HVR-L1, HVR-L2, and HVR-L3. Additionally, the present specification provides a library containing polynucleotides encoding a plurality of unique antibodies, each antibody comprising a heavy chain variable region and a light chain variable region. Also provided are an antibody, a polypeptide library, a vector library, a cell, a non-human animal, an antibody medium, a method for manufacturing an antibody library, a kit, and a method for manufacturing a bispecific antibody associated therewith.

The present application provides an anti-human CD153 monoclonal antibody, or a binding fragment thereof, that specifically binds to human CD153 and inhibits the intermolecular interaction between human CD153 and CD30. The present application further provides: a chimeric antigen receptor comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signal transduction domain wherein the extracellular antigen binding domain comprises a single-chain antibody having a heavy chain hypervariable region and a light chain hypervariable region which are the same as those of the monoclonal antibody of the present application; the invention also discloses a CAR-T cell for expressing the chimeric antigen receptor. The monoclonal antibody, the binding fragment of the monoclonal antibody and the CAR-T cell can be used for treating or preventing diseases related to CD153, such as multiple sclerosis. The invention provides the anti-human CD153 monoclonal antibody or the binding fragment of the anti-human CD153 monoclonal antibody which specifically binds to human CD153 and inhibits intermolecular interaction between the human CD153 and CD30. The present application further provides: a chimeric antigen receptor comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signal transduction domain wherein the extracellular antigen binding domain comprises a single-chain antibody having a heavy chain hypervariable region and a light chain hypervariable region which are the same as those of the monoclonal antibody of the present application; the invention also discloses a CAR-T cell for expressing the chimeric antigen receptor. The monoclonal antibody, the binding fragment thereof and the CAR-T cell can be used for treating or preventing diseases related to CD153, such as multiple sclerosis.

The application discloses a kind of paragallinarievaccines and preparation method thereof, the paragallinarievaccines include A type paragallinarie, B type paragallinarie and C type paragallinarie HMTp210 hypervariable region protein and avian pathogenic escherichia coli ghost.The application uses three serotypes HMTp210 hypervariable region recombinant protein and avian pathogenic escherichia coli ghost (especially O78 type avian pathogenic escherichia coli ghost) in combination, synergistically enhances humoral and cellular immunity, provides more broad-spectrum protection, while reaching the protection effect equivalent to white oil adjuvant, significantly improves injection safety, avoids the granuloma and other side reactions of white oil adjuvant, realizes the technical goal of "equivalent protection, better safety".